Chapter 30: Anti-Viral Medications

Anti-Viral Medications systematically surveys the pharmacological principles and drug strategies used to combat viral infections by targeting distinct stages of viral replication and lifecycle progression. The discussion begins with herpes family viruses, examining DNA polymerase inhibitors that prevent viral nucleic acid synthesis in herpes simplex and varicella-zoster infections, including mechanism-based agents and their clinical applications for resistant strains. The chapter then expands into comprehensive antiretroviral therapy for HIV, organizing treatment approaches by their specific points of viral lifecycle intervention. Entry inhibition strategies prevent the virus from attaching to or fusing with host cells, while reverse transcriptase inhibitors block the conversion of viral RNA into DNA for both nucleoside and non-nucleoside classes. Integrase inhibitors prevent the integration of viral genetic material into the host genome, a critical step in establishing persistent infection. Protease inhibitors disrupt the final maturation stage of newly synthesized viral particles, rendering them non-infectious. The chapter also discusses emerging monoclonal antibody approaches and addresses the clinical problem of drug-resistant viral strains requiring alternative therapeutic options. Beyond HIV and herpesviruses, the text covers respiratory virus management, contrasting older adamantane agents with modern neuraminidase inhibitors for influenza treatment by comparing their mechanisms and clinical efficacy. The chapter concludes with miscellaneous antiviral agents including broad-spectrum immunomodulatory compounds and their applications across various viral diseases. Throughout, the emphasis remains on understanding how different drug classes interrupt specific viral processes, enabling rational therapeutic selection based on viral type, site of infection, resistance patterns, and individual patient factors.